Complications (fever) Presence of fever · acute bleeding gastric varices in people with portal hypertension
It is very uncertain whether cyanoacrylate 1 mL changes complications (fever) Presence of fever compared with cyanoacrylate 0.5 mL (very low certainty).
1 finding from 1 review
All‐cause mortality · children with portal hypertension and large oesophageal varices, without previous gastrointestinal bleeding or beta‐blocker treatment
It is very uncertain whether band ligation changes all‐cause mortality compared with sham or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events Idiopathic thrombocytopaenic purpura · children with portal hypertension and large oesophageal varices, without previous gastrointestinal bleeding or beta‐blocker treatment
It is very uncertain whether band ligation changes serious adverse events Idiopathic thrombocytopaenic purpura compared with sham or no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · children with portal hypertension and large oesophageal varices, without previous gastrointestinal bleeding or beta‐blocker treatment
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Oesophageal variceal bleeding · children with portal hypertension and large oesophageal varices, without previous gastrointestinal bleeding or beta‐blocker treatment
It is very uncertain whether band ligation changes oesophageal variceal bleeding compared with sham or no intervention (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · children with portal hypertension and large oesophageal varices, without previous gastrointestinal bleeding or beta‐blocker treatment
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 30 days · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes all‐cause mortality at 30 days compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
All‐cause mortality at 5 years · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes all‐cause mortality at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
Number of participants with Variceal rebleeding episodes at 30 days · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes number of participants with Variceal rebleeding episodes at 30 days compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
Reintervention Number of women with reintervention · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes number of participants with reintervention at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
Irreversible shunt occlusion at 5 years · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes irreversible shunt occlusion at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
Encephalopathy · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes number of participants with encephalopathy at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with cirrhotic portal hypertension
1 finding from 1 review